Next Wave in Immune Therapeutics

From suppression to re-balancing the immune system

On 29-30 September 2020, Johnson & Johnson Innovation, in collaboration with Janssen Immunology, will host a virtual scientific and partnering event on state-of-the-art developments in immunology, bringing together entrepreneurs, start-ups, researchers, and scientists from across EMEA and beyond.

Immunology is one of the most rapidly advancing fields of biomedical research. Discoveries in immunology have enabled better ways to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, inflammatory bowel disease and psoriasis. Despite these advances, only a ~16% of patients living with moderate to severe forms of immune-mediated diseases are treated with advanced therapies and less than half of those achieve clinical remission*.

At Johnson & Johnson we see that in order to tackle this unmet need, new boundaries are being pushed in immune therapeutics. Researchers and drug developers are going beyond the suppression of single cytokine signalling pathways to more holistic approaches that attempt to rebalance rather than suppress the immune system. This next wave of scientific innovation includes:

  • Novel MoAs that engage the immune system’s natural brakes or target the non-immune cells that amplify inflammation
  • Targeting immune therapeutics to specific tissues or immune-cell types
  • Novel modalities that open up previously undruggable immune targets
  • High dimensional immune profiling for biomarker discovery for target identification and patient stratification

Johnson & Johnson Innovation, in collaboration with Janssen Immunology, is seeking to gather entrepreneurs, biotech’s and academic researchers who are trying to push such boundaries for a discussion on harnessing the next wave of science and innovation in Immunology and how Johnson & Johnson could partner and support them in their journey.

Please find below an exciting programme, networking and partnering opportunities – all virtual, to keep everyone’s costs and travels to a minimum as we continue to cope with a worldwide pandemic.

* 2018 data for US, Japan and EU5. Sources include Decision Resources, Kantar Health, NIH, Journal of Investigative Dermatology, BMJ, Foster Rosenblatt research, ZS Associates, Truven Claims, Deloitte research, data on file

 

Agenda

29 September - Main Programme* (times in CEST)

15:00 The Janssen Immunology Innovation Landscape

David Lee | Global Immunology Therapeutic Area Head, Janssen Research & Development, LLC

15:25 Panel Discussion and Q&A: Next Wave in Immune Therapeutics - Harnessing Early Innovation

  • Houman Ashrafian | Managing Partner, SV Health Investors
  • David Lee | Global Immunology Therapeutic Area Head, Janssen Research & Development, LLC
  • Erika Pearce | Director, Max Planck Institute of Immunobiology and Epigenetics, and Founder of Rheos Medicines
  • Jason Witherington (moderator) | Vice President, Immunology Lead EMEA, Johnson & Johnson Innovation Centre (London)

16:15 Break

16:20 The Johnson & Johnson Innovation Co-Creation Model

Elena Fernandez-Kleinlein | Head of JLABS EMEA, Johnson & Johnson Innovation

Nerida Scott | Head of Johnson & Johnson Innovation EMEA

16:40 Showcasing Immunology Innovators (5-min quick pitches)

17:00-18:00 Thematic Roundtables & Networking

 

REGISTER FOR THE MAIN PROGRAMME

* This session will be recorded 

 

30 September (10:00-18:00 CEST) 1:1 partnering meetings

Meeting the Johnson & Johnson Innovation Team

We interested to meet one-to-one with early-stage companies and researchers interested in presenting their technology/solutions and discussing potential collaboration opportunities.

Companies/researchers/organizations interested in a one-to-one meeting need to apply by 10 September EOD CEST.

APPLY FOR A 1:1 MEETING WITH US

Meeting other event participants

If you wish to meet other event participants during the partnering sessions or after the event, please ensure you tick the relevant box in the registration form and include a short bio/description of yourself/your company/your work. This will allow us to share your details with other participants in advance of the event.

Please note that you are responsible for reaching out to participants you are interested to meet, and for arranging these meetings (including any videoconferencing requirements). Only 1:1 meetings with the Johnson & Johnson Innovation team will be scheduled and facilitated by the event organising team.

To the speakers